Phase II clinical trial on docetaxel in the treatment of non-small-cell lung cancer (NSCLC)

• DOI: 10.1200/jco.2005.23.16_suppl.7352
• Publication Date: 2017-02-23T13:55:09Z
• Authors: Y. Chen; Y. Zhao; Z. Chen; M. Liao
• Keywords: Group B; Bone marrow suppression

7352 Purpose: To investigate the efficacy and safety of Docetaxel plus cisplatin regiment every week 3 weeks in patents with non-small-cell lung cancer (NSCLC). Methods: Patients NSCLC were divided into two groups. A group: randomly assigned to receive (Taxotere) 33mg/m2 d1, 8, 15 75mg/m2 d1 4 weeks. B Results: 14 patients evaluable for efficacy. Overall response rates 50%, group 40%, 55.5% respectively. Response rate was higher than A. The major toxicities neutropenia, nausea, vomiting, alopecia. There no grade IV bone marrow depression observed Neutropenia common (P>0.05). Grade singultus one patient withdraw study. Hypotension 1 patient, BP 90/60mmHg, recovered treatment. Middle survival time 25.8 months, 24 months B. year 100%, 84.6% Conclusion: regimens are an effective well-tolerated NSCLC. A, but No significant financial relationships disclose.